A ttempts to increase the antigenicity and immunogenicity of tumors have been made for Ͼ20 years. These modifications can be achieved by introducing allogeneic major histocompatibility complex molecules, cytokine genes, viruses, or costimulatory molecules such as B7-1 and B7-2 into tumor cells. 1 Numerous studies in different tumor and mouse models have established that the transfection of cytokine genes such as interleukin-2 (IL-2), IL-4, IL-7, IL-10, IL-12, GM-CSF, or interferon-␥ (IFN-␥) into tumor cell lines can protect mice against inoculation with these modified autologous cells. In some situations, protection against later challenge with unmodified cells or even a rejection of established tumors was achieved. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Although Ͼ30 clinical protocols worldwide have been designed and initiated to augment the immune response against cancer by cytokine transduction, 14 the administration of cytokine-engineered autologous tumor cells to patients is hampered by several major drawbacks. The establishment of autologous tumor cell lines and their transfection with cytokines is a time-consuming, laborious, and expensive procedure that is frequently unsuccessful. In addition, genetically modified tumor cells from different patients may vary in terms of the level and stability of cytokine expression and other molecular properties, making a comparison of clinical and biological effects difficult. Roth et al used cytokine-secreting allogeneic and xenogeneic cell lines to overcome these limitations and showed that the coadministration of such cells with syngeneic tumor cells could control tumor growth in several mouse and rat models, mainly through the activation of natural killer (NK) cells. 15 To test this specific immunotherapy strategy in a situation that mimics more closely the biology of human tumors, we have produced a genetically modified monkey fibroblast cell line secreting high levels of human IL-2 (Vero-IL-2) to treat the spontaneous fibrosarcomas and melanomas of domestic animals. Using these xenogeneic, IL-2-secreting cells, we demonstrated in a con-trolled study in Ͼ60 cats and dogs that repeated adjuvant injections of the engineered cells into the tumor bed after surgery and local irradiation substantially improved disease-free and overall survival in the treated animals compared with controls treated by standard therapy alone. 16 In cats with fibrosarcomas, long-term survival and the probably cure of Vero-IL-2 treated animals was 70%, compared with 30% in animals treated with surgery and irradiation alone. In canine melanomas, Vero-IL-2 treatment more than tripled the median survival of dogs compared with controls treated with standard tumor resection and external beam radiotherapy. 16 Interestingly, a local injection of either IL-2 or unmodified Vero cells alone led to decreased rather than improved survival in some additional cats and dogs included in this study, supporting the notion that both cytokine stimulation and the nonspecific effects of the xenogeneic cells are necessary to mediate the therapeutic effect. 16 In this report, we describe the use of Vero-IL-2 to treat patients with advanced solid tumors by repeated injections of cytokine-secreting xenogeneic cells. We demonstrate that the intratumoral (i.t.) administration of Vero-IL-2 is safe and shows biological and clinical effects.
PATIENTS AND METHODS

Patient eligibility
Patients with locally advanced or metastatic tumors accessible to injection either directly or by ultrasound or computed tomography (CT) guidance were potentially eligible for the study. In addition to the injected lesion, patients were required to have at least one other tumor site measuring Ͼ1 cm in diameter to evaluate eventual distant responses to therapy. Other eligibility criteria included: failure of and progression after all conventional treatments such as chemotherapy, radiotherapy, and surgery; Karnofsky performance status of Ն70%; estimated life expectancy of Ն3 months; age between 18 and 75 years; absence of other severe diseases that could potentially compromise treatment with Vero-IL-2; no chemo-, immuno-, or radiotherapy in the 4 weeks preceding study entry; and written informed consent. Patients with brain metastases and those taking steroids were excluded from the study.
Clinical protocol and patients
After approval of the Vero-IL-2 clinical protocol by the Schweizerische Kommission für Biologische Sicherheit (Swiss Commission for Biological Safety), the local ethical committee of the Kantonsspital Basel, and the Interkantonale Arzneimittelstelle (National Drug Safety Agency), we started including patients into the study in January 1996. Patients who met all of the inclusion and none of the exclusion criteria and who had given written informed consent were hospitalized for Ն5 days to receive three injections of 5 ϫ 10 5 (dose level 1), 5 ϫ 10 6 (dose level 2), or 5 ϫ 10 7 (dose level 3) Vero-IL-2 cells (TG2001 product) suspended in a total volume of 1.0 mL (dose levels 1 and 2) and 1.4 mL (dose level 3) of medium, respectively. Dose escalation in individual patients was not allowed, and Ն2 weeks of observation passed between the last patient on a dose level and the first on the next higher level. The cells were administered on Monday (day 1), Wednesday (day 3), and Friday (day 5) of the same week. In the absence of any signs of toxicity, patients could be discharged Ն6 hours after the last injection on day 5. Follow-up visits took place on days 8, 15, 22, and 29; months 2, 3, and 6; and then as clinically appropriate. Tumor biopsies were performed on day 1 (before the first injection of cells), on day 5 (before the third injection of cells), and on day 15 .
From January to August 1996, nine patients (five females and four males), were included in the trial (Table 1) . Their median age was 56 years (range, 20 -66). Three patients suffered from soft-tissue sarcomas, two from renal cell carcinomas, and one each from colon carcinoma, melanoma, urothelial carcinoma of the bladder, and carcinoma of the submandibular gland. In three patients, injection into large subcutaneous (s.c.) metastases without visualization was possible, although ultrasound guidance was used for biopsies. Two patients with liver metastases were biopsied and injected with the aid of ultrasound visualization; in four patients, CT guidance was used for all procedures (Table 1) . Following CT or ultrasound localization of the tumor, optimized access to the viable tumor parenchyma was planned. An automated 14-Gauge or 18-Gauge tru-cut needle biopsy was taken after local anesthesia. The core length was 2.3 cm. The injection of 1.0 or 1.4 mL of medium containing Vero-IL-2 cells was performed through a 20-Gauge injection needle that was also placed under CT guidance.
To monitor the potential toxic effects of the administration of Vero-IL-2, we evaluated clinical, biochemical, hematological, and hemodynamic parameters. A complete blood cell count and serum electrolyte, calcium, creatinine, hepatic enzymes, urine analysis, lymphocyte subpopulations, and antiVero antibodies (Abs) were obtained at baseline, at days 1, 3, and 5, and during follow-up visits. Temperature, blood pressure, respiratory rate, and cardiac rhythm were measured every 4 hours during hospitalization and later during follow-up visits.
Evaluation of tumor response
Although it was considered to be a secondary endpoint of this study, tumor status was determined clinically and radiologically before therapy, at months 1, 2, 3, and 6, and after that as clinically appropriate. Responses were evaluated according to the World Health Organization criteria as requested in a recent comprehensive review of cancer gene therapy trials.
14 Dose, preparation, and administration of Vero-IL-2 cells Vero-IL-2 stock (Transgène, Strasbourg, France) was prepared according to current Good Medical Practice regulations as described previously, 16 including extensive testing for potential viral and other contaminating agents; 3.6 ϫ 10 7 cells in 1 mL of freezing medium (Dulbecco's modified Eagle's medium (DMEM), 2 mM L-glutamine, 1% nonessential amino acids, 0.1% human serum albumin, and 5% dimethylsulfoxide; Transgène) were stored in cryotubes in liquid nitrogen. At 30 minutes before injection, cells were thawed at 37°C in a water bath, transferred on ice, and diluted in 1.0 or 1. PBLs were snap-frozen in Eppendorf tubes on dry ice and stored at Ϫ70°C.
Preparation of RNA and cDNA from clinical samples RNA was prepared from snap-frozen tumor biopsies and PBLs according to the RNAzol method 17 using a commercial RNA extraction kit (Socochim, Lausanne, Switzerland). Singlestrand cDNA was synthesized from 1 to 5 g of total RNA using the Superscript ribonuclease H-reverse transcriptase (RT) kit (Life Technologies).
Vector detection in peripheral blood and tumor specimens
To indirectly determine the persistence of Vero-IL-2 cells in tumor patients, specific polymerase chain reaction (PCR) amplification of exogenous human IL-2 cDNA was performed. 16 The final volume of the amplification reaction was 100 L containing 10 mmol tris(hydroxymethyl)aminomethane/HCl (pH 8.1), 1.5 mmol MgCl 2 , 50 mmol KCl, 0.1 g gelatin, 2.5 mmol deoxynucleoside triphosphate, 100 pmol of primers IL-2TGP5 (TAC CGC ATG CAA CTC CTG TCT TGT) and IL-2TGP3 (GCC AGA AGT CAG ATG CTC AAG), 2.5 U of AmpliTaq Gold polymerase (Perkin-Elmer, Rotkreuz, Switzerland), and cDNA prepared from tumor biopsies and PBLs. Amplification was performed on a PerkinElmer Cetus DNA thermal cycler (cat. no. N801-0150) using the following amplification protocol: 94°C for 10 minutes, 62°C for 40 seconds, and 72°C for 1 minute for one cycle; 94°C for 40 seconds, 62°C for 40 seconds, and 72°C for 1 minute for 34 cycles. To determine the level of sensitivity of detection of Vero-IL-2 cells on a background of cells not expressing IL-2, RNA was extracted from mixtures of K562 and Vero-IL-2 cells. The expression of IL-2 was determined by RT-PCR and subsequent analysis by high performance liquid chromatography 18 using a diethylaminoethyl-NPR column (no. N930-2656, Perkin-Elmer). Using this method, 50 Vero-IL-2 cells were easily detected on a background of 5 ϫ 10 6 K562 cells.
T-cell receptor (TCR) repertoire
The repertoire of T cells present in PBLs and tumor samples collected before and after the administration of Vero-IL-2 cells was studied using a new high-resolution RT-PCR method based on the determination of the TCR ␤-chain complementarity-determining region 3 (CDR3) transcript length. 19 -21 cDNAs were amplified in saturating PCR conditions (40 cycles) with a panel of experimentally validated 5Ј sense primers specific for the 24 BV subfamilies (including two pseudogenes) and one 3Ј antisense primer for the BC gene segment. Aliquots (2 L) of the BV1-24/BC PCR products were subjected to a three-cycle runoff reaction using a dyelabeled oligonucleotide primer specific for the BC gene segment. The runoff products were then run on an automated sequencer in the presence of fluorescent size markers. The length of the DNA fragments and the fluorescence intensity of the bands were analyzed with Immunoscope software. 19 Size variations of the runoff products are strictly due to differing CDR3 lengths, reflecting the imprecise V/D/J joining mechanism. In the PBLs of healthy donors, the repertoire of any BV-BC combination usually displays a bell-shaped profile with 3-nucleotide-spaced peaks corresponding to in-frame sequences. In contrast, the emergence of one or more dominant peaks reveals the presence of cDNAs with in-frame CDR3 regions of identical size, and thus possibly T-cell clones. 21 
Immunocytochemistry of tumor biopsies
After each biopsy, material was sent to histopathology for microscopical evaluation and immunocytochemistry. Biopsies were stained with commercially available Abs against CD4, CD8, CD25 (IL-2 receptor), and CD56/57 (NK cells), and staining was quantified as "Ϫ" (no positive cells), "(ϩ)" (0 -10% positive cells), "ϩ" (10 -25% positive cells), "ϩϩ" (25-50% positive cells), and "ϩϩϩ" (Ͼ50% positive cells) for each Ab.
Expression analysis of i.t. cytokines by PCR
The i.t. presence of T cells (CD3) and the expression of ILs (IL-2, IL-4, IL-6, IL-10, tumor necrosis factor-␣ (TNF-␣), and IFN-␥) were analyzed with cDNA samples prepared from the biopsies by quantitative PCR as described previously using the following primer pairs (Pharmacia Biotech AB):
22 ␤-actin, ACT-S2 (5Ј-GGG AAA TCG TGC GTG ACA TT-3Ј) and ACT-AS2 (5Ј-GGA GTT GAA GGT AGT TTC GTG-3Ј); CD3, CD3P5 (5Ј-CTG GAC CTG GGA AAA CGC ATC-3Ј) and CD3P3 (5Ј-GTA CTG AGC ATC ATC TCT CGA TC-3Ј); IL-2, IL-2RNA5 (5Ј-ATG TAC AGG ATG CAA CTC CTG TCT T-3Ј) and IL-2RNA3 (5Ј-GTC AGT GTT GAG ATG ATG CTT TGA C-3Ј); IL-4, IL-4RNA5 (5Ј-ATG GGT CTC ACC TCC CAA CTG CT-3Ј) and IL-4RNA3 (5Ј-CGA ACA CTT TGA ATA TTT CTC TCT CAT-3Ј); IL-6, IL-6RNA5 (5Ј-ATG AAC TCC TTC TCC ACA AGC GC-3Ј) and IL-6RNA3 (5Ј-GAA GAG CCC TCA GGC TGG ACT G-3Ј); IL-10, IL-10RNA5 (5Ј-AAG GCA TGC ACA GCT CAG CAC T-3Ј) and IL-10RNA3 (5Ј-TCC TAG AGT CTA TAG AGT CGC CA-3Ј); TNF-␣, TFNARNA5 (5Ј-ATG AGC ACT GAA AGC ATG ATC CGG-3Ј) and TNFARNA3 (5Ј-GCA ATG ATC CCA AAG TAG ACC TGC CC-3Ј); IFN-␥ IFN-GRNA5 (5Ј-ATG AAA TAT ACA AGT TAT ATC TTG GCT TT-3Ј) and IFNGRNA3 (5Ј-GAT GCT CTT GCA CCT CGA AAC AGC AT-3Ј).
cDNA preparations from phytohemagglutinin-stimulated PBLs from healthy donors were used as positive controls to detect cytokine expression and the presence of T cells.
Cytotoxicity assay
Killer cell activities of PBLs from tumor patients and healthy controls against K562 (NK) cells, Daudi (lymphokine activated killer (LAK)) cells, anti-carcinoembryonic antigen (Ag) Ab-coated (Dako, Zug, Switzerland) AsPC1 (Ab-dependent cell-mediated cytotoxicity) cells, and Vero-IL-2 cells were estimated by the 51 Cr release (Amersham, Little Chalfont, UK) technique. A total of 5000 51 Cr-labeled target cells were incubated with effector cells at various effector to target ratios (50, 10, 2, or 0.4) in 100 L of RPMI 1640 with 10% FCS at 37°C for 4 hours. Aliquots of the radioactive supernatants were measured in a ␥-counter, and cytotoxicity was calculated by the following formula: % specific release ϭ ([cpm (experimental) Ϫ cpm (spontaneous)]/[cpm (maximal) Ϫ cpm (spontaneous)]) ϫ 100. Spontaneous release was determined without adding effector cells and maximal release was obtained by detergent lysis of target cells.
Mixed lymphocyte reaction
The proliferative response of PBLs from tumor patients and healthy donors to allogeneic stimulator cells was determined by incubating 1 ϫ 
Flow cytometric analysis (FACScan) of leukocyte subpopulations
Flow cytometry was performed on a FACScan flow cytometer (Becton Dickinson, Mountain View, Calif) using Lysis II software for data processing as described recently. 23 To characterize the different leukocyte populations in the peripheral blood of tumor patients and healthy controls, the following monoclonal Abs (mAbs) were used: CD3 (UCHT-1), CD4 (Q4120), CD8 (UCHT-4), CD11b (mAb 44), CD14 (UCHM-1), CD16 (BL-LGL/1), human histocompatibility leukocyte Ag (W6/32) (Sigma-Aldrich Chemie, Buchs, Switzerland), CD19 (HIB19) (PharMingen, Hamburg, Germany), CD25 (M-A251), CD56 (B159), and DR (TÜ 36) (Dianova, Hamburg, Germany). Binding specificity was determined using immunoglobulin G1 (IgG1) (MOPC-21), IgG2a (UPC-10), and IgG2b (MOPC-141) isotype control mAbs (Sigma-Aldrich Chemie).
ELISA detection of serum cytokines
Serum cytokine levels during Vero-IL-2 treatment were determined in undiluted serum samples using commercial IL-2, IL-4, IL-6, IL-10, TNF-␣, and IFN-␥ ELISA kits (R&D Systems Europe) according to the manufacturer's instructions. Serum samples from a patient having received 6 ϫ 10 6 international units of intravenous (i.v.) recombinant human IL-2 served as a positive control for systemic IL-2 levels.
Screening for anti-Vero Abs
To detect serum Abs against Vero cells, the plasma or sera of patients were centrifuged (1500 ϫ g, 30 minutes) and incubated with Vero cells for 2 hours at 37°C. Next, horseradish peroxidase-conjugated polyclonal goat Abs against human IgG heavy and light chains (Jackson ImmunoResearch Laboratories, West Grove, Penn) and o-phenylene diamine (Sigma, St. Louis, Mo) were added, and cells were washed and analyzed on a Kinetic Microplate reader (Molecular Devices, Sunnyvale, Calif). Samples were considered positive if optical densities after treatment were Ͼ2.5-fold higher than pretreatment levels.
RESULTS
Evaluation of injected cells
Before injection, a small aliquot of freshly thawed cells was analyzed for viability and cell number and subsequently cultured for 4 -24 hours to measure IL-2 secretion. The median number of injected viable cells during 27 applications on three dose levels (5 ϫ 10 5 , 5 ϫ 10 6 , and 5 ϫ 10 7 ) was 98% of intended values (range, 63-156%); median viability of cells was 82% (range, 65-92%); median amount of IL-2 produced by injected cells was 229 ng/10 6 cells/24 hours/mL (range, 106 -515 ng/mL).
Analysis of peripheral blood
Serum levels of endogenous IL-2, IL-4, IL-6, IL-10, TNF-␣, and IFN-␥ on day 1 of treatment were low and not different from those in untreated healthy controls (n ϭ 9; data not shown). Despite important differences in the baseline levels of serum IL-2 between treated patients, a statistically significant (P Ͻ .05) increase of IL-2 could be observed on day 5 of treatment; this increase returned to baseline values by day 15 (Fig 1a) . Two patients showed major transient increases of serum levels of IL-6, IL-10, and IFN-␥, including patient 8, during a short period of fever, but this difference was not statistically significant for the group as a whole due to the high variability of baseline levels. The serum levels of IL-4 and TNF-␣ did not change during or after treatment with Vero-IL-2 (data not shown).
FACScan analysis of PBLs did not indicate significant changes in the composition or activation state of lymphocyte subpopulations (data not shown). Cellular reactivity, as determined by mixed lymphocyte reaction, NK, LAK, and Ab-dependent cell-mediated cytotoxicity assays, was also identical on days 1, 5, and 15 of treatment. Interestingly, all patients and nine different healthy controls showed an important NK-like cytotoxic activity against Vero-IL-2 cells in PBLs that was not influenced by the i.t. application of Vero-IL-2 cells in patients. In contrast, a systemic i.v. application of IL-2 in control patients rapidly enhanced NK, LAK, and anti-Vero-IL-2 cytotoxicity (data not shown).
Analysis of tumor biopsies
Tumor biopsies of the injection sites were performed on days 1 and 5, before the injection of Vero-IL-2, and on day 15. An increased tumor infiltration by either CD4 ϩ lymphocytes on days 5 and/or 15 compared with pretreatment levels was observed in eight of nine patients (Table 2 ), but there was no clear pattern as to which lymphocyte population increased posttreatment. Thus, the numbers of CD4 ϩ , CD8 ϩ , CD25 ϩ , and CD56/57 ϩ lymphocytes in the tumor biopsies increased in three, four, five, and one patient, respectively. However, a decrease in one or more of these markers was also observed in three of nine patients (Table 2) .
Tumor biopsy samples were also assayed by RT-PCR for mRNA expression of cytokines (IL-2, IL-4, IL-6, IL-10, TNF-␣, and IFN-␥) and CD3. Whereas mRNA encoding for ␤-actin was detectable in all 26 tested samples, no expression of exogenous IL-2 mRNA (i.e., of the transgene) was observed in the tumor biopsies of days 1, 5, and 15, most likely reflecting a rapid destruction of Vero cells by the immune system of the patient. A statistically significant increase in CD3 mRNA was detected in tumor biopsies on day 5 of treatment compared with pretherapeutic levels that had returned to baseline on day 15 (P Ͻ .05 , Fig 1b) , indicating transient infiltration of injected sites by T lymphocytes. Similarly, there was a nonsignificant trend toward increased expression of IL-10 and TNF-␣ in the tumor biopsies on day 5, whereas IL-4, IL-6, and IFN-␥ mRNA was detected at approximately the same levels in tumor biopsies from days 1, 5, and 15 (data not shown).
TCR repertoire CDR3 size analysis has been shown to be a powerful method to detect T-cell clonal expansion in uncultured blood and tissue samples, and also to provide a good overall appraisal of the T-cell repertoire. 19 -21 We focused our analysis of the TCR repertoire on patient 1 (sarcoma), who achieved a tumor response, and on patient 4 (melanoma), who developed vitiligo and stabilization of a previously progressing tumor for 9 months (see below). Figure 2 , lane A shows that most of the BV-BC PCR products from the PBLs of patient 4 (melanoma) that were collected before the administration of Vero-IL-2 displayed a bell-shaped profile with several 3-nucleotide-spaced peaks, as found in healthy human donors. In contrast, the patterns were rather irregular in the PBLs from patient 1 (sarcoma), even before the start of gene therapy (Fig 2, lane B) , with a large number of predominant peaks in different BV subfamilies (see BV3, BV5, BV9, and BV16). Interestingly, this restricted repertoire appeared to be highly stable over time, because the profile from the blood samples collected 15 (data not shown) and 366 days later (Fig 2, lane C) were very similar (see BV2, BV5, BV6, and BV9). In the tumor biopsy taken from the sarcoma patient before Vero-IL-2 administration (Fig 2, lane D) , there was also a highly restricted repertoire with a very unusual number of dominant peaks in the different 
NA, not available; ca., carcinoma. For a definition of staining intensities ("ϩ") see Materials and Methods.
BV-BC profiles (see BV3, BV6, BV7, BV13, BV14, BV15, BV16, and BV17). The CDR3 lengths of the prominent peaks were distinct from those observed in the corresponding blood samples, ruling out an artifact due to blood contamination of tumor samples. Vero-IL-2 treatment did not profoundly modify this restricted repertoire, and similar profiles were obtained in the three successive tumor samples collected on days 3, 5 (data not shown), and 15 (Fig 2, lane E) following the administration of Vero-IL-2. A tumor sample collected 1 year after treatment also exhibited BV-BC profiles with prominent peaks (Fig 2, lane F) , but with different CDR3 lengths compared with the earlier tumor samples. Overall, the TCR repertoire of patient 1 (sarcoma) was extraordinarily restricted in PBLs and tumor samples but did not seem to be influenced by Vero-IL-2 treatment. In contrast, the diverse repertoire observed in the PBLs of patient 4 (melanoma) (Fig 2, lane A) underwent rapid and substantial modifications, with the appearance of predominant peaks only 2 days after treatment (see BV3, BV7, BV13, and BV15; Fig 2, lanes G and H) . Unfortunately, despite repeated attempts, no cDNA of sufficient quality for TCR analysis was available from the melanoma of patient 4 before the first injection with Vero-IL-2. Therefore, despite a very restricted T-cell repertoire in the injected melanoma on days 3 and 5 postinjection demonstrating several predominant peaks (data not shown), we could not prove a modification of the i.t. TCR repertoire caused by the treatment, as was shown for the T-cell repertoire in the peripheral blood of this patient.
Toxicity
The injection procedure was well tolerated by all patients, and minor pain and minimal hematoma at the injection site were the only procedure-related toxicities observed. Patients 1 and 2 developed mild, self-limited itching and erythema of the trunk on days 12 and 13, and patient 8 experienced a fever of Յ39.8°C lasting for 12 hours on day 5, after the third injection of Vero-IL-2. No eosinophilia, lymphocytosis, or leukocytosis and no increase of serum Igs were observed during these episodes of fever, erythema, and pruritus. No laboratory abnormalities and no signs of organ toxicity related to the experimental therapy were observed in any of the patients. Patients 6 and 8 developed Abs against Vero cells at 2 weeks after therapy ended.
Clinical course and tumor response
The clinical characteristics of the patients, their prior therapies, and their response to Vero-IL-2 are summarized in Table 1 . Three patients progressed after therapy and died at 4, 5, and 5 months, respectively. One patient, patient 9, developed peritonitis after perforation of the colon by a noninjected intra-abdominal metastasis of her leiomyosarcoma. She died 4 weeks after injection and was not evaluable for response. Autopsy proved that there was no possible association between the injection of Vero cells and bowel perforation. Four patients showed stabilization of disease for 3, 7, 9, and 9 months, respectively. Interestingly, a patient with melanoma (patient 4) with an intra-abdominal metastasis of 9.0 ϫ 6.0 ϫ 6.0 cm diameter (whose tumor remained stable for 9 months after Vero-IL-2 therapy) developed marked vitiligo on both arms, the trunk, and her forehead at 3 months postinjection (Fig 3) . This patient had been in progression after treatment with systemic IL-2, IFN, and three different chemotherapy regimens before injection with Vero cells (Table 1) . Curiously, the color of the biopsy cores obtained from her tumor on days 1, 5, and 15 were black, brown, and white, respectively, suggesting depigmentation of the injected melanoma metastasis following treatment with Vero-IL-2. Although her tumor finally progressed after 9 months of stable disease, this patient showed a remarkably stable course of her disease and is alive with very slow progression of her tumor at 24 months after therapy.
Patient 1 suffered from a leiomyosarcoma originating from the lower limb with histologically proven metastases to the right elbow (4 cm diameter), left parotic gland (3.5 cm diameter), and skull (2.5 cm diameter). He had been in progression after seven cycles of CyVADIC chemotherapy immediately before inclusion into the study. At 2 months after a 3-fold injection of the elbow metastasis with 5 ϫ 10 5 Vero-IL-2 cells, the metastasis in the parotic gland started to decrease in size; at 12 months after therapy, a reduction of its volume by Ͼ90% could be demonstrated by magnetic resonance imaging (MRI) (Fig 4) . Similarly, the other noninjected metastasis to the skull decreased in volume by ϳ50% (Fig 4) , whereas the injected elbow metastasis remained unchanged in size for 12 months and showed signs of necrosis upon MRI scanning. This impressive response of the parotic gland metastasis has now lasted for Ͼ27 months, although the patient is relapsing at other sites, with a progression of his skull metastasis at 26 months and the development of new pulmonary and soft-tissue metastases at 24 months. The patient has been retreated with a total of six i.t. injections with Vero-IL-2 cells into a soft-tissue metastasis; the last injection was 1 month before this report). The retreatment was also tolerated without any signs of toxicity, and the patient is clinically stable.
DISCUSSION
IL-2 is a potent immunostimulatory molecule that has led to tumor responses in renal cell cancer and melanoma in 15-25% of selected patients. 24 However, the potential toxicities of high doses of IL-2 are severe, and the vast majority of cancer patients does not benefit from systemic treatment with this or other cytokines. The successful induction of an antitumor immune response by IL-2 transfection into murine cancer cell lines 5, 6 ,25 inspired a series of clinical studies using IL-2 transfected autologous or allogeneic tumor cells in patients with different malignancies. 14 We have used IL-2 transfected xenogeneic Vero fibro- Vero-IL-2, the metastasis in the parotic gland started to decrease in size; at 12 months after therapy, a reduction of its volume by Ͼ90% was seen (see arrows). The second noninjected metastasis to the skull also decreased in volume by ϳ50% (see arrows). The scans shown were done immediately before (left) and 12 months after (right) therapy.
blasts in a controlled adjuvant trial to treat dogs and cats with spontaneous sarcomas and melanomas. 16 The Vero cell line was selected as the most appropriate cellular vector for hIL-2 production due to its excellent characterization and safety records, which were established during the pharmaceutical production of human poliovirus vaccine. 16 In Ͼ60 domestic animals treated in a nonrandomized controlled trial, we were able to show a substantial increase of cure rate in cats with fibrosarcomas treated with standard therapy plus Vero-IL-2 compared with animals treated with standard therapy alone (70% vs. 30%). Similarly, the survival of dogs with buccal melanoma was markedly improved by an injection of Vero-IL-2 into the tumor bed after surgery and irradiation. 16 Experiments in mice had shown that the mechanism of action of this immune response induced by xenogeneic, cytokine-secreting cells was most likely mediated by NK cells and, to a lesser degree, also by CD4 ϩ and CD8
ϩ cells. 15 Although we could not perform extensive immunological analyses in the domestic animals treated for reasons of practicability, and thus the mechanism of this preclinical proof of efficacy remains unclear, 16 the results were encouraging enough to lead to the implementation of a clinical phase I study in patients with advanced solid tumors.
The primary goal of this study was to determine the feasibility and safety of a repeated i.t. administration of Vero-IL-2 in humans. A secondary goal was the evaluation of the biological and clinical effects of this experimental treatment. The rationale of our approach was severalfold: to create a local environment favoring an antitumor immune response through the close proximity of specific (hypothesized tumor Ags) and nonspecific (IL-2; xenogeneic Ags) immune stimulants and to achieve higher i.t. but lower systemic concentrations of IL-2 compared with i.v. or s.c. administration. In addition, compared with the transfection of autologous tumor cells with a cytokine, 14 this approach would be much more practical, cheaper, and more easily available should it ever be used in a larger number of cancer patients. Finally, compared with the use of allogeneic, cytokine-transfected cell lines, the introduction of xenoAgs on the surface of the Vero cells might provide a valuable, nonspecific ("adjuvant") immune stimulus in addition to the high local production of cytokine. Interestingly, two recent clinical studies on the immunotherapy of melanoma have confirmed a similar concept using very different approaches. It was shown that both IL-2 and a strong unspecific adjuvant stimulus such as keyhole limpet hemocyanin were necessary in addition to tumor-specific melanoma Ag peptides to induce tumor regression in patients with far-advanced melanomas. 26, 27 From the data obtained in the tumor biopsies and peripheral blood samples of the patients treated in this study, we cannot, however, conclusively determine a possible mechanism of action of Vero-IL-2 cells in humans. An increase of either CD4 ϩ , CD8 ϩ , or NK cells infiltrating the tumor biopsies was observed in most patients, and a statistically significant increase of CD3 mRNA in tumor biopsies on day 5 compared with pretreatment levels (reflecting an increase in the number of tumor-infiltrating T cells) could be shown for the entire group of patients (see Fig 1b) . However, these changes were only subtle, transient, and perhaps clinically irrelevant; clearly, a more thorough evaluation of a larger number of uniformly treated patients with the same type of tumor is needed to draw any firm conclusions.
Similarly, we currently cannot prove that any biological or clinical effect seen after an injection of Vero-IL-2 cells in patients was due to the combination of both the xenogeneic cells as well as the transgene; although unlikely, it is conceivable that treatment with unmodified Vero cells might have similar effects as the approach used in our gene therapy trial. In preclinical studies in mice as well as in dogs and cats, however, protection against tumor growth was not achieved when IL-2 alone or unmodified Vero cells were used for treatment. 15, 16 The primary goals of our study, regarding the evaluation of feasibility and toxicity of an i.t. application of Vero-IL-2 cells, however, has been met. Indeed, the insignificant toxicity of treatment and the low IL-2 levels in the sera of our patients demonstrate that Vero cells were either rapidly cleared from or never reached circulation in relevant numbers. Similarly, the absence of exogenous IL-2 mRNA in the tumor biopsies on days 5 and 15 was most likely due to a very short half-life of Vero cells in vivo. This possibility is supported by the excellent sensitivity of our detection method (Ͻ1:10 5 ), the high amounts of IL-2 produced by injected cells (Ͼ200 ng/10 6 cells/24 hours/mL), the quality of the isolated mRNA (␤-actin expression in 26 of 26 biopsies), and the exact guidance of biopsy needles to previously injected sites by CT or ultrasound. Our findings of only minor changes in nonspecific tests such as serum cytokine concentrations and cellular cytotoxicity assays were also expected given the local nature of treatment. There was also no sign of a dose response effect of any of the biological and clinical endpoints of this study. Because of the heterogenous group of patients treated in this phase I study, the absence of known tumor-specific Ags in most malignancies, and the lack of sufficient tumor material from the majority of our patients, more specific tests such as cytotoxic T-lymphocyte precursor 28 or peptide recognition assays 29 could not be performed. Although tumor response was not a primary endpoint of this study and the selection of highly pretreated patients (see Table 1 ) made responses to any therapy unlikely, our clinical observations deserve some comments. Although tumor stabilization for several months (observed in four of nine patients with previously progressive malignancies) might have been induced by Vero-IL-2 injection, it would also be compatible with the natural course of disease; we observed at least two signs of some clinical activity of Vero-IL-2 cells (i.e., vitiligo and depigmentation of the injected metastasis in a patient with melanoma and tumor shrinkage in another patient with soft-tissue sarcoma).
It has been shown that the presence of a growing melanoma can sensitize patients to melanocyte-differentiation Ags and that the immune response against these Ags is associated with cancer regression in patients undergoing immunotherapy. 30, 31 In a recent study of metastatic melanoma, 11 patients developed vitiligo. Although no loss of pigmentation was seen in those 27 patients who did not respond to immunotherapy, 11 of 43 (26%) patients who had an objective response to IL-2-based immunotherapy did develop vitiligo. 32 Although our patient with melanoma (patient 4) did not show a tumor response, her clinical course was remarkable, because a very large, previously progressive abdominal metastasis stopped growing for 9 months after injection with Vero-IL-2. It is suggestive that the observed depigmentation of her pretherapeutically normal skin (see Fig 3) and of the biopsied injected tumor was due to an immune response induced by i.t. injection with Vero-IL-2. Interestingly, this patient also showed an induction of restricted peaks in the analysis of the TCR repertoire of PBLs (Fig 2) and some increase of tumor infiltration with CD8 ϩ cells on day 15. Although, due to the limited data available, we cannot prove that this effect was a consequence of the treatment with IL-2-transfected xenogeneic cells and could not be achieved by treatment with either IL-2 or Vero cells alone, our findings do support the concept of the induction of an immune response mediated by Vero-IL-2 treatment. Unfortunately, a restriction also of the i.t. TCR repertoire in this patient could not be demonstrated due to technical problems with the pretherapeutic melanoma sample (see Results).
Clinically, the most important finding was the impressive, long-lasting (Ͼ29 and 26 months, respectively) reduction of the size of two distant, noninjected sarcoma metastases in the heavily pretreated patient 1 (Table 1) . This reduction demonstrates the potential of Vero-IL-2 therapy to induce antitumor responses. It is tempting to speculate that Vero-IL-2 therapy has triggered a preexisting antitumor immune response mediated by extraordinarily restricted, pre-existing T-cell clones in the peripheral blood and tumor of patient 1 (Fig 2) . Again, no firm conclusions can be drawn due to the limitations in the number of patients analyzed; therefore, this hypothesis needs to be studied further, combining phenotypical, functional, and molecular characterization of these T-cell clones. It is conceivable that the T-cell anergy caused by the inability of tumor cells to express appropriate costimulatory molecules might be overcome by Vero-IL-2 treatment. 33 In conclusion, the i.t. application of Vero-IL-2 in nine patients with advanced solid tumors was safe and accompanied by little toxicity. Although efficacy was not an endpoint of this phase I study and although the tumor response seen in one patient with sarcoma should not be overinterpreted, we believe that an additional evaluation of i.t. treatment with Vero-IL-2 is warranted. A multicentric, randomized phase II study comparing repeated cycles of i.t. injection with two different doses of Vero-IL-2 in melanoma patients has recently been initiated in five centers in France and Switzerland. The goal of that study is to better determine the efficacy and potential mechanisms of action of this new approach to gene therapy of cancer.
